The CD44v6 CAR-T cells exhibited potent anti-leukemic effects [54,55] indicating that CD44v6 is a rational target of CAR-T therapy for AML harboring FLT3 or DNMT3A mutations. The gene discussed is DNMT3A; the disease is acute myeloid leukemia.